# Silexion Therapeutics Corp. SLXN

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0002022416


# None

**No letter**

3 of 14 inputs computable; 7 are required, with a score in every sleeve


| Scoreboard | |
|---|---|
| **Reliability** | 0.76 AUC<br>filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025 |
| **Peer failure rate** | 0.60% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | under $12.5M assets<br>total assets $7.2M |
| **Warnings** | short runway, thin data<br>not computable: dilution, degenerate inputs, distress, fortress balance sheet |
| **Inputs computable** | 3 of 14 |
| **Graded from** | filings received through May 19, 2026<br>166 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026 |
| **Last close** | $0.15<br>2026-10-30; market equity $0; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 17, 2026*

Unless the context otherwise requires, in this "Business" section, the terms "we," "us" and "our" generally refer to: (i) for the period following the Closing of the Business Combination on August 15, 2024, Silexion Therapeutics Corp (formerly known as Biomotion Sciences), a Cayman Islands exempted company ("Silexion") and its consolidated subsidiaries, including Silexion Therapeutics Ltd., an Israeli company ("Silexion Israel"), through which our business is primarily conducted, and, (ii) with respect to all periods prior to and through the Closing of the Business Combination, Silexion Israel and its subsidiaries.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 19.9** | | | | | | |
| Gross profitability | not computable | 32.4% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| *one or more required annual facts are missing* | | | | | |
| Accruals ratio | (21.7%) | (6.6%) | 19.9 | 803 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 0* | | | | | |
| **Solvency, sleeve percentile 73.2** | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | |
| *firm-wide XBRL shares cannot be assigned to one ticker class* | | | | | |
| Altman Z double-prime | (31.64) | (0.35) | 81.5 | 748 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | 2.41x | 2.92x | 65.0 | 829 | 2025-12-31 |
| **Growth and financing** | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | |
| *four annual observations are required; found 0* | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | |
| *four consecutive annual FCF observations are required; found 2* | | | | | |
| Reinvestment rate | not computable | 37.1% | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | |
| Asset growth, three years | not computable | 2.2% | | | |
| *four annual observations are required; found 2* | | | | | |
| Net share issuance, one year | not computable | 2.5% | | | |
| *firm-wide XBRL shares cannot be assigned to one ticker class* | | | | | |

## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Short runway | cash runway is 2.2 months |
| Thin data | 3 of 14 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-10-30 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (99.2%) | (2.2%) | 0 |
| Distance from 52-week high | (99.6%) | (28.7%) | 0 |
| EBIT to enterprise value | not computable | (1.4%) | |
| Free cash flow yield | not computable | (1.0%) | |
| Book value to price | not computable | 0.28 | |
| Sales to price | not computable | 0.30 | |
| Composite equity issuance, five years | not computable | 20.5% | |
| Relative strength against the sector, log excess return | (4.95) | (0.19) | 0 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Current ratio improved | pass |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $2.2M |
| Operating cash flow, four quarters | -$12.4M |
| Months of runway | 2.2 |
| Days since last periodic filing | 79 (10-Q received Aug 14, 2026) |
| Median daily dollar volume, 63 sessions | $262,605 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$11.9M | 2025-12-31 | 2026-03-17 | 10-K | 26-000953 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$10.8M | 2025-12-31 | 2026-03-17 | 10-K | 26-000953 |
| 3 | assets | us-gaap:Assets | $7.2M | 2025-12-31 | 2026-03-17 | 10-K | 26-000953 |
| 4 | assets | us-gaap:Assets | $2.9M | 2024-12-31 | 2026-03-17 | 10-K | 26-000953 |
| 5 | current assets | us-gaap:AssetsCurrent | $6.6M | 2025-12-31 | 2026-03-17 | 10-K | 26-000953 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $2.8M | 2025-12-31 | 2026-03-17 | 10-K | 26-000953 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$55.2M | 2025-12-31 | 2026-03-17 | 10-K | 26-000953 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$11.6M | 2025-12-31 | 2026-03-17 | 10-K | 26-000953 |
| 9 | book equity | us-gaap:StockholdersEquity | $2.6M | 2025-12-31 | 2026-03-17 | 10-K | 26-000953 |
| 10 | liabilities | us-gaap:Liabilities | $4.6M | 2025-12-31 | 2026-03-17 | 10-K | 26-000953 |
| 11 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $9,000 | 2025-12-31 | 2026-03-17 | 10-K | 26-000953 |
| 12 | depreciation amortization | us-gaap:Depreciation | $14,000 | 2025-12-31 | 2026-03-17 | 10-K | 26-000953 |
| 13 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$11.9M | 2025-12-31 | 2026-03-17 | 10-K | 26-000953 |
| 14 | income tax | us-gaap:IncomeTaxExpenseBenefit | $3,000 | 2025-12-31 | 2026-03-17 | 10-K | 26-000953 |
| 15 | current assets | us-gaap:AssetsCurrent | $2.2M | 2024-12-31 | 2026-03-17 | 10-K | 26-000953 |
| 16 | current liabilities | us-gaap:LiabilitiesCurrent | $3.5M | 2024-12-31 | 2026-03-17 | 10-K | 26-000953 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.